Babesiosis
diseaseOn this page
Also known as Babesia caused disease or disorderBabesia disease or disorderBabesia infectious diseaseBabesia parasite infectionbabesiasisHuman babesiosisinfection by Babesiapiroplasmosis
Summary
Babesiosis (MONDO:0005661) is a disease and 4 clinical trials. Top therapeutic interventions include tafenoquine. A subtype of protozoa infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Europe)
- Phenotypes (HPO): 31
- Clinical trials: 4
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | <1 / 1 000 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
31 HPO clinical features (Orphanet curated; top 31 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001878 | Hemolytic anemia | Very frequent (80-99%) |
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002315 | Headache | Very frequent (80-99%) |
| HP:0000952 | Jaundice | Frequent (30-79%) |
| HP:0000975 | Hyperhidrosis | Frequent (30-79%) |
| HP:0001744 | Splenomegaly | Frequent (30-79%) |
| HP:0001873 | Thrombocytopenia | Frequent (30-79%) |
| HP:0001882 | Leukopenia | Frequent (30-79%) |
| HP:0002240 | Hepatomegaly | Frequent (30-79%) |
| HP:0002719 | Recurrent infections | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0012735 | Cough | Frequent (30-79%) |
| HP:0000083 | Renal insufficiency | Occasional (5-29%) |
| HP:0000613 | Photophobia | Occasional (5-29%) |
| HP:0000716 | Depression | Occasional (5-29%) |
| HP:0001259 | Coma | Occasional (5-29%) |
| HP:0001289 | Confusion | Occasional (5-29%) |
| HP:0001376 | Limitation of joint mobility | Occasional (5-29%) |
| HP:0001399 | Hepatic failure | Occasional (5-29%) |
| HP:0001635 | Congestive heart failure | Occasional (5-29%) |
| HP:0001658 | Myocardial infarction | Occasional (5-29%) |
| HP:0001864 | Clinodactyly of the 5th toe | Occasional (5-29%) |
| HP:0002017 | Nausea and vomiting | Occasional (5-29%) |
| HP:0002039 | Anorexia | Occasional (5-29%) |
| HP:0002093 | Respiratory insufficiency | Occasional (5-29%) |
| HP:0004936 | Venous thrombosis | Occasional (5-29%) |
| HP:0005521 | Disseminated intravascular coagulation | Occasional (5-29%) |
| HP:0100724 | Hypercoagulability | Occasional (5-29%) |
| HP:0100776 | Recurrent pharyngitis | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | babesiosis |
| Mondo ID | MONDO:0005661 |
| EFO | EFO:0007162 |
| MeSH | D001404 |
| Orphanet | 108 |
| DOID | DOID:9643 |
| ICD-10-CM | B60.0 |
| ICD-11 | 1947003329 |
| NCIT | C84581 |
| SNOMED CT | 21061004 |
| UMLS | C0004576 |
| MedGen | 2523 |
| GARD | 0005878 |
| MedDRA | 10003965 |
| NORD | 832 |
| Is cancer (heuristic) | no |
Also known as: Babesia caused disease or disorder · Babesia disease or disorder · Babesia infectious disease · Babesia parasite infection · babesiasis · Human babesiosis · infection by Babesia · piroplasmosis
Disease family
This is a subtype of protozoa infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › babesiosis
Related subtypes (14): primary amebic meningoencephalitis, granulomatous amebic encephalitis, trypanosomiasis, giardiasis, protozoal dysentery, trichomoniasis, malaria, Acanthamoeba keratitis, amebiasis, balantidiasis, coccidiosis, theileriasis, leishmaniasis, dientamoebiasis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Tafenoquine.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06207370 | PHASE2 | RECRUITING | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis |
| NCT06656351 | PHASE2 | RECRUITING | B-FREE Chronic Babesiosis Study |
| NCT06478641 | Not specified | AVAILABLE | Expanded Use in Persistent (B. Microti) Babesiosis |
| NCT07345988 | Not specified | RECRUITING | Human Babesiosis in Metropolitan France |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TAFENOQUINE | 4 | 3 |
Related Atlas pages
- Drugs: Tafenoquine